Dr. Savidge research interests include studying microbiome-neuroimmune interactions in the gastrointestinal tract. This work has established new microbiome biomarkers of gastrointestinal disease susceptibility, as well as identifying novel innate host defense mechanisms which are being pioneered as “allosteric therapeutics”.
Pan-Microbiome Profiling Identifies Enterotype-Specific Taxa And Metagenomic Functions For Diarrheal Disease Classification
Rita Colwell, Johns Hopkins Bloomberg School of Public Health
Manoj Dadlani, CosmosID
Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the Microbiome field and panel discussions on the challenges for faster adoption.